BillionToOne, Inc. (BLLN)
104.02
+1.26
(+1.23%)
USD |
NASDAQ |
Dec 04, 16:00
106.00
+1.98
(+1.90%)
Pre-Market: 08:26
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 4.723B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -- |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 22.25 |
| Price to Book Value | -- |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.6309 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | -- |
Profile
| BillionToOne, Inc. develops DNA molecular counting technology. It can detect disorders such as sickle cell disease and cystic fibrosis. The company was founded by Oguzhan Atay, Sukrit Silas, and David Tsao and is headquartered in Palo Alto, CA. |
| URL | http://www.billiontoone.com |
| Investor Relations URL | N/A |
| HQ State/Province | California |
| Sector | |
| Industry | |
| Next Earnings Release | N/A |
| Last Earnings Release | N/A |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| BillionToOne, Inc. develops DNA molecular counting technology. It can detect disorders such as sickle cell disease and cystic fibrosis. The company was founded by Oguzhan Atay, Sukrit Silas, and David Tsao and is headquartered in Palo Alto, CA. |
| URL | http://www.billiontoone.com |
| Investor Relations URL | N/A |
| HQ State/Province | California |
| Sector | |
| Industry | |
| Next Earnings Release | N/A |
| Last Earnings Release | N/A |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |